# cystic fibrosis complications gut disease and pancreatic

**Published:** 2026-08-04T15:22:33.138Z  
**Topic:** Cysic  
**Sentiment:** neutral  
**Publisher:** TrendWatcher — https://www.trendwatcher.in/article/a1b194ab-a587-4256-8b1b-a7e382f2a0eb

cystic fibrosis complications include gut disease, pancreatic insufficiency and cancer risk; learn the key facts and upcoming treatment developments in under

Cystic fibrosis patients now face a growing burden of gastrointestinal complications, with exocrine pancreatic insufficiency (EPI) affecting nutrition and quality of life for thousands of Australians and Americans alike【1】.  

| At a glance | |
|---|---|
| Affected Australians | ~3,800 |
| US patients (estimate) | ~40,000 |
| Predicted survival age (born 2019‑2023) | 64 years |
| New $250 M investment to cut pill burden | Anagram Therapeutics |

## Gastrointestinal disease is now a major health challenge  
Historically, CF was viewed primarily as a lung disorder, but early signs often appear in the gut, with bowel obstruction, severe constipation and gastro‑oesophageal reflux reported across all ages【1】. As survival improves, adults with CF are experiencing higher rates of colorectal cancer at younger ages than the general population, a risk that was previously under‑recognised because few lived long enough for cancers to develop【1】.  

## Treatment gaps and a $250 M push to ease pancreatic insufficiency  
For people with EPI due to CF, current therapy can require up to 40 pills daily, a regimen that drives non‑adherence and side‑effects such as weight loss and abdominal pain【3】. Blackstone Life Sciences has pledged $250 million to support Anagram Therapeutics’ ANG003, an oral recombinant enzyme replacement designed to reduce the pill burden to three per day. The phase‑2 study will compare ANG003 with AbbVie’s Creon, the existing pancreatic enzyme replacement therapy【3】.  

## Ongoing limitations of CFTR modulators  
While CFTR modulators have extended life expectancy and improved lung function, their impact on gastrointestinal symptoms remains modest. Early‑childhood treatment can partially restore pancreatic function, yet many patients still suffer from malnutrition, gut inflammation and persistent liver disease, leaving a substantial unmet need for better gut‑focused therapies【1】.  

## What to watch  
- **Clinical trial progress:** enrollment and safety results from ANG003’s phase‑2 study, slated to begin later this year.  
- **Regulatory milestones:** FDA decisions on new CFTR modulators that may address gastrointestinal outcomes.  
- **Cancer screening guidelines:** updates to colorectal cancer screening recommendations for CF patients as survival ages rise.  

The shift from a lung‑centric view to a whole‑body perspective underscores that extending lifespan without addressing gut complications may leave patients vulnerable to malnutrition and cancer, highlighting the urgency for therapies that target the gastrointestinal side of cystic fibrosis.

## Sources
1. The Conversation — [Cystic fibrosis doesn’t just affect the lungs. It’s a gut disease too](https://theconversation.com/cystic-fibrosis-doesnt-just-affect-the-lungs-its-a-gut-disease-too-283769)
2. USA Today — [Everything to know about cystic fibrosis and what causes it](https://www.usatoday.com/story/life/health-wellness/2025/02/10/what-is-cystic-fibrosis/78030828007/)
3. FierceBiotech — [Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication](https://www.fiercebiotech.com/biotech/blackstone-invests-250m-anagram-reduce-burden-cf-complication)

---
Cite as: TrendWatcher, "cystic fibrosis complications gut disease and pancreatic", https://www.trendwatcher.in/article/a1b194ab-a587-4256-8b1b-a7e382f2a0eb